Subtotal versus total gastrectomy for mid- and distal gastric poorly cohesive carcinoma: a retrospective controlled study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 4/4)
유사 논문P · Population 대상 환자/모집단
154 patients were included.
I · Intervention 중재 / 시술
Subtotal
C · Comparison 대조 / 비교
total gastrectomy for mid
O · Outcome 결과 / 결론
Our study demonstrated that subtotal gastrectomy yielded oncologic outcomes similar to those achieved with total gastrectomy in mid- and distal gastric poorly cohesive carcinoma cases.
[BACKGROUND] Subtotal gastrectomy is frequently performed for distally located gastric tumors and carries a lower risk of postoperative complications compared to total gastrectomy.
- 추적기간 79 months
APA
Dinçer B, Sağdıç MF, et al. (2025). Subtotal versus total gastrectomy for mid- and distal gastric poorly cohesive carcinoma: a retrospective controlled study.. Frontiers in oncology, 15, 1717678. https://doi.org/10.3389/fonc.2025.1717678
MLA
Dinçer B, et al.. "Subtotal versus total gastrectomy for mid- and distal gastric poorly cohesive carcinoma: a retrospective controlled study.." Frontiers in oncology, vol. 15, 2025, pp. 1717678.
PMID
41367862 ↗
Abstract 한글 요약
[BACKGROUND] Subtotal gastrectomy is frequently performed for distally located gastric tumors and carries a lower risk of postoperative complications compared to total gastrectomy. However, due to the submucosal spread pattern and worse prognosis of poorly cohesive carcinoma (PCC), some authors advocate for routine total gastrectomy. This study aimed to compare the outcomes of subtotal versus total gastrectomy in patients with mid- and distal-located gastric PCC.
[METHODS] This single-center retrospective study included patients who underwent resection for gastric PCC between 2012 and 2024. Exclusion criteria were systemic metastasis, palliative surgery, and tumors located in the proximal one-third of the stomach. Patients were analyzed based on demographic, clinical, pathological, and survival data.
[RESULTS] A total of 154 patients were included. The median age was 62 years (range: 36-87), and 83 patients (53.9%) were male. Subtotal gastrectomy was performed in 70 patients (45.5%). The median pathological tumor diameter was 60 mm (IQR: 40-90). Over a median follow-up of 79 months, 33 locoregional and 81 systemic recurrences were observed among 146 patients, and 53 patients (36.3%) were alive at the time of last follow-up. Pathological stage was the only independent factor associated with overall survival, while the type of surgery (subtotal vs. total gastrectomy) did not significantly affect survival outcomes.
[CONCLUSION] Our study demonstrated that subtotal gastrectomy yielded oncologic outcomes similar to those achieved with total gastrectomy in mid- and distal gastric poorly cohesive carcinoma cases.
[METHODS] This single-center retrospective study included patients who underwent resection for gastric PCC between 2012 and 2024. Exclusion criteria were systemic metastasis, palliative surgery, and tumors located in the proximal one-third of the stomach. Patients were analyzed based on demographic, clinical, pathological, and survival data.
[RESULTS] A total of 154 patients were included. The median age was 62 years (range: 36-87), and 83 patients (53.9%) were male. Subtotal gastrectomy was performed in 70 patients (45.5%). The median pathological tumor diameter was 60 mm (IQR: 40-90). Over a median follow-up of 79 months, 33 locoregional and 81 systemic recurrences were observed among 146 patients, and 53 patients (36.3%) were alive at the time of last follow-up. Pathological stage was the only independent factor associated with overall survival, while the type of surgery (subtotal vs. total gastrectomy) did not significantly affect survival outcomes.
[CONCLUSION] Our study demonstrated that subtotal gastrectomy yielded oncologic outcomes similar to those achieved with total gastrectomy in mid- and distal gastric poorly cohesive carcinoma cases.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in -amplified gastric cancer.
- Association of preoperative frailty and prognostic nutritional index with postoperative delirium in elderly gastric cancer patients: A single-center observational study.
- Treating a single tumor deposits as two lymph node metastases can improve the accuracy of gastric cancer prognosis assessment.
- Complete response to Nivolumab-based chemotherapy in a case of advanced gastric cancer with multiple immune-related adverse events.
- Apatinib and silver nanoparticles synergize against gastric cancer through the PI3K/Akt signaling pathway-mediated ferroptosis.